Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

NCT07408089 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer

Interventions

DRUG: BBI-940
DRUG: Fulvestrant

Sponsor

Boundless Bio, Inc.